Through its newly acquired EU-GMP distribution
hub in Germany, Khiron expands its
product portfolio and geographic reach within Europe to
Germany, UK, and Switzerland.
- Switzerland: Khiron
enters the Swiss medical cannabis market with the first sales of
two of its new flower products, namely the KHIRON Gelato 19/1 and
the first THC:CBD balanced flower product KHIRON Caramel 5/7
- UK: Marking the 1st year anniversary of
Zerenia™ Clinics UK, Khiron also initiated sales of three new
exclusive products in the UK, consolidating a strong portfolio and
improving selection for patients and prescribers
- Germany: After
obtaining import approvals from German regulators, Khiron will
start selling a total of seven medical cannabis SKU's in the
upcoming weeks
TORONTO, Nov. 16,
2022 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or
the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), announces its market entry
into Switzerland with initial
sales of new products and increases its product offerings in
Germany and UK.
In August 2022, Khiron completed
the acquisition of its EU GMP-certified manufacturer and
wholesaler, Pharmadrug GmbH in Germany. Since then, the Company has obtained
import and export permits across Germany and the UK bringing to market its new
product offerings, as well as looking for opportunities to expand
its presence in other European markets.
The Alpine Republic of Switzerland has become the next market for
Khiron, with Khiron's established reputation in Germany helping to pave the way. The start of
the expansion is marked by the availability of the flower products
KHIRON Gelato 19/1 and KHIRON Caramel 5/7, which are already very
popular amongst patients and prescribers in our established
markets.
Recently, a survey was conducted among all patients of Zerenia™
Clinics UK, with 100% of respondents stating that they are
satisfied that their quality of life has improved since starting
treatment. This service experience for patients is complemented by
Khiron's steadily growing product portfolio, which has just
recently been expanded with three additional exclusive varieties
that will offer new treatment options for prescribers and
patients.
Franziska Katterbach, President of Khiron Europe, comments:
"Khiron continues its tradition of entering new markets early and
furthering our goal of improving the lives of our patients in all
our target markets. We are very excited to improve lives of
patients in Switzerland as of now.
I am equally pleased that our one-year anniversary of Zerenia™
Clinics UK is marked by the very good feedback from patients
treated in our clinic. This reinforces our patient-first and
quality first-approach which we will now bring to Switzerland as well."
About Khiron Life Sciences
Corp.
Khiron is a leading global medical cannabis company with core
operations in Latin America and
Europe. Leveraging wholly-owned
medical health clinics and proprietary telemedicine platforms,
Khiron combines a patient-oriented approach, physician education
programs, scientific expertise, product innovation, and focus on
creating access to drive prescriptions and brand loyalty with
patients worldwide. The Company has a sales presence in
Colombia, Germany, the United
Kingdom, Switzerland,
Peru, and Brazil. The Company is led by its co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced and diverse executive
team and board of directors.
Visit Khiron online at https://investors.khiron.ca.
LinkedIn:
https://www.linkedin.com/company/khiron-life-sciences-corp/
Cautionary Statement Regarding
Forward-Looking Information
This press release may contain "forward-looking information"
within the meaning of applicable securities legislation. All
information contained herein that is not historical in nature
constitutes forward-looking information. Forward-looking
information contained in this news release may include statements
pertaining to the expected synergies and benefits to the Company
from the acquisition of the Target as well as statements as to
business strategy. Forward-looking information and statements
contained in this news release reflect management's current beliefs
and is based on information currently available and on assumptions
that management believes to be reasonable. These assumptions
include, but are not limited to, the expected benefits to be
realized by Khiron's business as a result of the acquisition of the
Target, and assumptions regarding market opportunities in the
jurisdictions in which the Company operates and where it seeks to
operate.
Although management believes that its expectations and
assumptions to be reasonable, forward-looking information is always
subject to known and unknown risks, uncertainties and other
factors, many of which are beyond the control of management, that
may cause actual results to differ materially from those expressed
or implied in such forward-looking information. Such risks and
uncertainties include but are not limited to the following: general
economic conditions, adverse conditions in capital markets,
political uncertainties, counterparty risk, failing to obtain
required regulatory requirements and approvals, failure to maintain
required permits and licences, business integration risks, as well
as those other risk factors discussed in Khiron's most recent
annual information form which is available on Khiron's SEDAR
profile at www.sedar.com.
As a result of the foregoing and other risks and uncertainties,
readers are cautioned not to place undue reliance on
forward-looking information contained in this press release.
Readers are further cautioned that the foregoing risks and
uncertainties is not exhaustive, and there may be other risks and
uncertainties, presently unknown to management of the Company, that
may cause actual results to differ materially from those expressed
or implied in forward-looking statements contained in this press
release. The forward-looking information contained in this press
release is expressly qualified by this cautionary statement. Khiron
disclaims any intention to update or revise any forward-looking
information disclosed herein, whether as a result of new
information, future events or otherwise, except as required by
law.
NEITHER THE TSX VENTURE EXCHANGE, NOR ITS REGULATION SERVICES
PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX
VEMTIRE EXCHANGE), ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS PRESS RELEASE.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-begins-sales-in-switzerland-and-expands-its-medical-cannabis-portfolio-in-germany-and-the-united-kingdom-301680030.html
SOURCE Khiron Life Sciences Corp.
